Exploratory analysis of the visceral disease subgroup in a phase III study of abiraterone acetate in metastatic castration-resistant prostate cancer

被引：0
|
作者：
O B Goodman
T W Flaig
A Molina
P F A Mulders
K Fizazi
H Suttmann
J Li
T Kheoh
J S de Bono
H I Scher
机构：
[1] Comprehensive Cancer Centers of Nevada,Department of Medical Oncology
[2] University of Colorado Cancer Center,undefined
[3] Janssen Research & Development,undefined
[4] Radboud University Medical Centre,undefined
[5] Institut Gustave Roussy,undefined
[6] University of Paris Sud,undefined
[7] Urologikum Hamburg,undefined
[8] Janssen Research & Development,undefined
[9] The Institute of Cancer Research and The Royal Marsden Hospital,undefined
[10] Memorial Sloan-Kettering Cancer Center and Weill-Cornell Medical College,undefined
来源：
Prostate Cancer and Prostatic Diseases | 2014年 / 17卷
关键词：
abiraterone acetate; liver metastases; metastatic prostate cancer; survival; visceral disease;
D O I：
暂无
中图分类号：
学科分类号：
摘要：
引用
收藏
页码：34 / 39
页数：5
相关论文
共 50 条
  • [1] Exploratory analysis of the visceral disease subgroup in a phase III study of abiraterone acetate in metastatic castration-resistant prostate cancer
    Goodman, O. B., Jr.
    Flaig, T. W.
    Molina, A.
    Mulders, P. F. A.
    Fizazi, K.
    Suttmann, H.
    Li, J.
    Kheoh, T.
    De Bono, J. S.
    Scher, H. I.
    PROSTATE CANCER AND PROSTATIC DISEASES, 2014, 17 (01) : 34 - 39
  • [2] Abiraterone Acetate In Metastatic Castration-Resistant Prostate Cancer
    Yang, Lily P. H.
    DRUGS, 2011, 71 (15) : 2067 - 2077
  • [3] Exploratory analysis of the visceral disease (VD) patient subset in COU-AA-301, a phase III study of abiraterone acetate (AA) in metastatic castration-resistant prostate cancer (mCRPC)
    Goodman, Oscar B.
    Flaig, Thomas W.
    Molina, Arturo
    Mulders, Peter
    Suttmann, Henrik
    Li, Jinhui
    Kheoh, Thian San
    De Bono, Johann Sebastian
    Scher, Howard I.
    JOURNAL OF CLINICAL ONCOLOGY, 2013, 31 (06)
  • [4] Niraparib and Abiraterone Acetate for Metastatic Castration-Resistant Prostate Cancer
    Chi, Kim N.
    Rathkopf, Dana
    Smith, Matthew R.
    Efstathiou, Eleni
    Attard, Gerhardt
    Olmos, David
    Lee, Ji Youl
    Small, Eric J.
    Gomes, Andrea J. Pereira De Santana
    Roubaud, Guilhem
    Saad, Marniza
    Zurawski, Bogdan
    Sakalo, Valerii
    Mason, Gary E.
    Francis, Peter
    Ms, George Wang
    Wu, Daphne
    Diorio, Brooke
    Lopez-Gitlitz, Angela
    Sandhu, Shahneen
    JOURNAL OF CLINICAL ONCOLOGY, 2023, 41 (18) : 3339 - +
  • [5] Erratum to Abiraterone acetate: in metastatic castration-resistant prostate cancer
    L. P. H. Yang
    Drugs, 2012, 72 (2) : 192 - 192
  • [6] Abiraterone Acetate (Zytiga) for Metastatic Castration-Resistant Prostate Cancer
    不详
    MEDICAL LETTER ON DRUGS AND THERAPEUTICS, 2011, 53 (1370): : 63 - 64
  • [7] Abiraterone acetate in castration-resistant prostate cancer
    Iacovelli, Roberto
    Palazzo, Antonella
    Procopio, Giuseppe
    Gazzaniga, Paola
    Cortesi, Enrico
    ANTI-CANCER DRUGS, 2012, 23 (03) : 247 - 254
  • [8] Use of Prednisone With Abiraterone Acetate in Metastatic Castration-Resistant Prostate Cancer
    Auchus, Richard J.
    Yu, Margaret K.
    Nguyen, Suzanne
    Mundle, Suneel D.
    ONCOLOGIST, 2014, 19 (12): : 1231 - 1240
  • [9] A multicentre analysis of abiraterone acetate in Canadian patients with metastatic castration-resistant prostate cancer
    Clayton, Ravinder
    Wu, Jackson
    Heng, Daniel Y.
    North, Scott A.
    Emmenegger, Urban
    Hotte, Sebastien
    Chi, Kim
    Zielinski, Rob
    Al-Shamsi, Humaid
    Chen, Leo
    Eigl, Bernhard
    CUAJ-CANADIAN UROLOGICAL ASSOCIATION JOURNAL, 2014, 8 (9-10): : E583 - E590
  • [10] A Phase I Study of Capivasertib in Combination With Abiraterone Acetate in Patients With Metastatic Castration-Resistant Prostate Cancer
    Shore, Neal
    Mellado, Begona
    Shah, Satish
    Hauke, Ralph
    Costin, Dan
    Adra, Nabil
    Cullberg, Marie
    Teruel, Carlos Fernandez
    Morris, Thomas
    CLINICAL GENITOURINARY CANCER, 2023, 21 (02) : 278 - 285
12345